Regeneron Pharmaceuticals Inc (REGN)
883.99
-6.69
(-0.75%)
USD |
NASDAQ |
Apr 26, 14:56
Regeneron Pharmaceuticals Enterprise Value: 88.90B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 88.90B |
| April 24, 2024 | 90.64B |
| April 23, 2024 | 90.73B |
| April 22, 2024 | 89.94B |
| April 19, 2024 | 89.57B |
| April 18, 2024 | 89.26B |
| April 17, 2024 | 90.05B |
| April 16, 2024 | 89.28B |
| April 15, 2024 | 89.77B |
| April 12, 2024 | 90.44B |
| April 11, 2024 | 92.15B |
| April 10, 2024 | 93.90B |
| April 09, 2024 | 94.74B |
| April 08, 2024 | 94.15B |
| April 05, 2024 | 94.61B |
| April 04, 2024 | 93.99B |
| April 03, 2024 | 95.52B |
| April 02, 2024 | 95.93B |
| April 01, 2024 | 97.53B |
| March 28, 2024 | 96.78B |
| March 27, 2024 | 97.20B |
| March 26, 2024 | 96.90B |
| March 25, 2024 | 96.63B |
| March 22, 2024 | 97.30B |
| March 21, 2024 | 97.39B |
| Date | Value |
|---|---|
| March 20, 2024 | 97.27B |
| March 19, 2024 | 96.91B |
| March 18, 2024 | 96.50B |
| March 15, 2024 | 97.00B |
| March 14, 2024 | 96.40B |
| March 13, 2024 | 97.11B |
| March 12, 2024 | 97.67B |
| March 11, 2024 | 97.00B |
| March 08, 2024 | 97.48B |
| March 07, 2024 | 97.97B |
| March 06, 2024 | 97.84B |
| March 05, 2024 | 97.08B |
| March 04, 2024 | 97.74B |
| March 01, 2024 | 99.01B |
| February 29, 2024 | 97.18B |
| February 28, 2024 | 99.54B |
| February 27, 2024 | 100.17B |
| February 26, 2024 | 99.72B |
| February 23, 2024 | 98.84B |
| February 22, 2024 | 97.05B |
| February 21, 2024 | 95.72B |
| February 20, 2024 | 95.07B |
| February 16, 2024 | 95.20B |
| February 15, 2024 | 95.93B |
| February 14, 2024 | 95.17B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
27.20B
Minimum
Oct 02 2019
100.17B
Maximum
Feb 27 2024
62.01B
Average
62.90B
Median
Oct 16 2020
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 91.51B |
| Eli Lilly and Co | 711.57B |
| AbbVie Inc | 342.12B |
| Amgen Inc | 198.03B |
| Pfizer Inc | 201.07B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.160B |
| Revenue (Quarterly) | 3.434B |
| Total Expenses (Quarterly) | 2.431B |
| EPS Diluted (Quarterly) | 10.19 |
| Gross Profit Margin (Quarterly) | 84.95% |
| Profit Margin (Quarterly) | 33.77% |
| Earnings Yield | 3.93% |
| Operating Earnings Yield | 4.21% |
| Normalized Earnings Yield | 4.337 |